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Abstract
Objectives and design Inflammation has a prominent role
in the development of atherosclerosis. Type 2 diabetes
could contribute to atherosclerosis development by pro-
moting inflammation. This status might accelerate changes
in intrinsic vascular wall cells and favor plaque formation.
Cyclooxygenase 2 (COX-2) is highly expressed in athero-
sclerotic plaques. COX-2 gene expression is promoted
through activation of toll-like receptor 4 (TLR4) and pro-
inflammatory cytokine interleukin 1b (IL1-b). Aim of this
study is to investigate whether expression profiles of pro-
inflammatory genes such as COX-2, TLR4 and IL1-b in
atherosclerotic plaques are altered in type 2 diabetes (T2D).
Methods Total RNA was isolated from plaques of ath-
erosclerotic patients and expression of COX-2, TLR4, IL1-
b analyzed using real-time PCR. Histological analysis was
performed on sections of the plaque to establish the degree
of instability.
Results Statistically significant differences in mRNA
expression of COX-2 and IL1-b were found in plaques of
T2D compared with non-T2D patients. A multi-variable
linear regression model suggests that COX-2 mRNA
expression is affected by T2D pathology and IL1-b mRNA
expression in atherosclerotic plaques.
Conclusions Our results support the hypothesis that T2D
pathology contributes in vivo to increase the inflammatory
process associated with the atherosclerotic plaque forma-
tion, as shown by an increment of COX-2 and IL1-b
mRNA expression.
Keywords Cyclooxygenase 2  Inflammation 
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Introduction
Atherosclerosis is a chronic inflammatory disease of the
arterial wall [1] that affects 346 million people worldwide
and a cause of morbidity for 70 % of patients with type 2
diabetes (T2D) [2].
T2D accelerates the clinical course of atherosclerosis [3]
damaging mesangial and endothelial cells [4]. Arterial
endothelial cells normally resist attachment of the white
blood cells streaming past them. However, when subjected
to irritative stimuli, arterial endothelial cells express che-
moattractant molecules that beckon leukocytes to attach and
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migrate through the endothelial monolayer and enter the
arterial intima [5]. Irritative stimuli act as pro-inflammatory
agents that alter the behavior of intrinsic vascular wall cells
and trigger the production of prostanoids, a family of
pleiotropic lipid mediators, involved in vascular inflamma-
tion [6]. Important irritative stimuli that play a role in
atherosclerosis are dyslipidemia, [7, 8] hypertension, [9, 10]
cigarette smoke [11, 12] and diabetes (type 1 and 2) [3, 13,
14]. Cyclooxygenase 2 (COX-2) is the enzyme responsible
for the high output production of prostanoids (prostaglan-
dins and thromboxanes) from arachidonic acid in multiple
inflammatory pathophysiological conditions [15]. In par-
ticular, prostaglandin E2 (PGE2) plasma levels are increased
in inflammatory processes, like atherosclerosis [16]. COX-
2, an inducible enzyme that is normally absent from tissues
(with the exception of kidney and parts of the brain, where
COX-2 is constitutive) [17], is highly expressed in athero-
sclerosis lesions [18] and its expression is induced by a wide
range of inflammatory stimuli. Inflammation has a promi-
nent role in the development of atherosclerosis, and PGE2
expression may provide a link between risk factors, such as
T2D [19], and the cellular alterations that underlie the dis-
ease [5] and vascular complications [20]. In particular, Sheu
et al. [21] and Kellogg et al. [22] observed that high glucose
concentration can up-regulate COX-2 expression with the
induction of PGE2 in myocardial cells and umbilical vein
endothelial cells. Several studies suggest that COX-2
expression is promoted through activation of toll-like
receptor 4 (TLR4) [23, 24]. Recently, Ferronato et al. [25]
reported a coordinated up-regulation of COX-2 and TLR4
expression in peripheral blood of stroke patients, suggesting
that TLR4 might participate in the peripheral inflammatory
process after stroke in part through a COX-2 dependent
pathway. It has been reported that high glucose concentra-
tion promotes the expression of COX-2 through the
activation of IL1-b in mesangial cells [26] and islets of
Langerhans [27]. Although there is mounting evidence that
T2D contributes to the pathophysiology of atherosclerosis,
knowledge of the mechanism of action in the inflammatory
pathway is lacking. The aim of this study is to investigate
whether the mRNA expression profile of the pro-inflam-
matory genes COX-2, TLR4 and IL1-b is altered in T2D
patients and whether this altered expression could be
involved in the augmented inflammatory process in the
plaques of these patients.
Subjects and methods
Patients
Consecutive eligible patients with internal carotid artery
stenosis undergoing carotid endarterectomy at Verona
University Hospital were included in this study. A total of
60 patients, as detailed in Table 1, were selected for gene
expression analysis. They were all of Caucasian descent
from North-East Italy. The group included 23 patients who
presented transient ischemia attack (TIA) or ischemic
stroke and 37 with asymptomatic carotid plaques. In the
group of TIA and ischemic stroke six subjects had T2D. In
the asymptomatic carotid plaque group, eight subjects had
T2D (Table 1). The atherothrombotic nature of the event
was established as described by Ferronato et al. [25].
Characteristics of the patients, vascular risk factors,
current therapy information, and plaque histological ana-
lysis, are given in Table 2. Exclusion criteria included
intracerebral hemorrhage, inflammatory pathologies, and
non-steroidal or glucocorticoid anti-inflammatory therapy.
Smoking habit was defined as non or current smoker.
Current smokers were defined as individuals who smoked
any tobacco in the past 12 months and included those who
had quit within the past year. Non-smokers were defined as
subjects who never smoked. Ex-smokers were defined as
those who had quit more than a year earlier [28] and, if
they had quit more than 10 years earlier, they were con-
sidered non-smokers [29]. The study was approved by the
Ethical Committee of the Hospital and informed written
consent was obtained from all patients before enrollment.
RNA extraction from carotid plaques
Carotid plaques were retrieved from patients during carotid
endarterectomy and immediately placed in RNA later
solution (Ambion Inc) for RNA stabilization and protec-
tion. After being placed in RNA later and kept in ice, the
sample was taken to the laboratory by a staff member to be
processed. Total RNA from carotid plaques was purified by
ultracentrifugation in cesium chloride gradient.
Quantitative real-time PCR
Total RNA from whole carotid plaques was extracted by a
guanidinium thiocyanate/cesium chloride gradient method
and RNA from samples was reverse transcribed using a
complementary DNA (cDNA) synthesis kit (Invitrogen),
according to the supplier’s instructions. TLR4, COX-2 and
IL1-b gene expressions were determined by real-time RT-
PCR using Sybr Green I as described by Ferronato et al. [25].
PCR were performed in triplicate for each gene. Quality
control of the RNA was tested using non-denaturing agarose
gel electrophoresis verifying the integrity of the 18S RNA.
Histological analysis
Surgically removed carotid plaques were frozen in isopen-
tane and preserved at -80 C for histopathological analysis.
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Serial sections of the plaque were analyzed with hematox-
ylin and eosin to evaluate fibrous cap integrity, intraplaque
hemorrhage, calcium deposits, inflammatory infiltrate,
neovascularization lipid core and endoluminal thrombus.
For immunohistochemistry, obtained cryostat sections were
fixed in acetone at -20 C for 10 min, pre-incubated in PBS
with 3 % hydrogen peroxide and, after three washes, were
incubated in PBS with monoclonal mouse anti-human CD-
68 (Oncogene), anti-human HLA II (Dako) and anti-human
CD3 (Thermo Scientific). As secondary antibodies, biotin-
ylated antibodies IgG anti-rabbit and anti-mouse (Dako
Corporation, Carpinteria, CA) were used. After washing in
PBS, the sections were treated with ABC-Elite (Vector) and
the peroxidase activity highlighted by development in per-
oxidase substrate kit (Vector). Degree of plaque instability
was established on the basis of inflammatory infiltrate,
according to Lovett et al. [30]. For each plaque, the presence
and/or amount of the following features was recorded on a
simple grade scale: rupture of the fibrous cap, lipid core size,
nodular calcification, neovascularization, inflammatory
infiltrate, infiltration of the fibrous cap, proportion of fibrous
tissue, intraplaque hemorrhage, surface thrombus, number
of foam cells and overall instability.
Statistical analysis
Statistical analysis was managed with R version 2.13.1
(www.r-project.org). The Shapiro-Wilk test was applied to
check for normal distribution and the Bartlett test to check
for equal variances across samples. When not normally
distributed, values were logarithmically transformed. Dif-
ferences in gene expression were analyzed with Student’s
t test and the values were given as mean ± standard devi-
ation (SD). A multiple linear regression was fitted to the data
to determine the significance of covariates through the
stepwise method of R package ‘MASS’ version 7.3–19.
Hypertension and dyslipidemia were adjusted for the
patient’s therapies by adding the covariates (statins and ACE
inhibitor) to the regression model for each gene expression
level. The likelihood ratio test was performed using the R
package ‘epicalc’ version 2.15.1.0. The Baron and Kenny
[31] analytical procedure was used to determine the medi-
ator function of a third variable. The R package ‘pwr’
version 1.1.1 was used to check the statistical power based
on the sample size, standard deviation and mean to have type
2 error (beta)[80 %. A p-value \ 0.05 (type 1 error or alpha
\0.05) was considered statistically significant.
Results
In this study, we analyzed gene expression of COX-2,
TLR4, and IL1-b in atherosclerotic plaques in a group of
60 atherosclerotic patients. Sixteen were T2D and 43 were
non-T2D patients (missing data for one patient) (Table 1).
Along with T2D, other risk factors as smoking habit (mean
of cigarette exposure in current smokers is 29 ± 19 ciga-
rettes/day). All the ex-smokers quit more than 10 years
earlier and then considered as non-smokers, hypertension,
dyslipidemia, sex and age were considered in the analysis.
No differential mRNA expression was observed between
symptomatic and asymptomatic patients for all the three
genes analyzed (p-value [ 0.05, data not shown).
In addition, considering each degree of plaque instability
(grade 1 = stable, grade 2 = probably stable, grade
3 = probably unstable), no differential COX-2, TLR4, and
IL1-b mRNA expression was observed when comparing
asymptomatic with symptomatic patients. Thus, symptom-
atic and asymptomatic patients were considered as one
group.
COX-2 and IL1-b mRNA expressions were higher in
carotid plaques of patients with T2D compared to non-T2D
patients (1.67 ± 1.45 vs. 0.84 ± 0.72, p \ 0.01;
3.25 ± 2.41 vs. 1.04 ± 0.77, p \ 0.01, respectively).
Smoking habit increased significantly the expression of
COX-2 (1.57 ± 1.27 vs. 0.68 ± 0.53, p \ 0.01). TLR4
mRNA expression did not show statistical difference in any
of the risk factors considered (Table 3).
Correlation analysis in relation to T2D status
In T2D patients, a linear correlation between COX-2 and
TLR4 mRNA expression in plaques was observed
(R = 0.71, p \ 0.001), which was not observed in non-
T2D patients (R = 0.18, p [ 0.05). No correlation of
COX-2 and TLR4 mRNA expression was observed for any
of the other non genetic risk factors analyzed (data not
shown). A correlation was observed between COX-2 and
IL1-b mRNA expression in T2D (R = 0.69, p \ 0.05) and
non-T2D patients (R = 0.49, p \ 0.001). Although the
linear correlation in non-T2D patients appeared weaker, the
difference between the two groups was not statistically
significant as determined by the Pearson correlation.
mRNA expression and plaque instability
COX-2 and IL1-b
In the entire population, considering the degree of the
overall plaque instability, a statistically significant linear
correlation between COX-2 and IL1-b mRNA expression
was observed in grade 2 (R = 0.61, p = 0.001) and grade
3 (R = 0.75, p = 0.03). Considering foam cells composi-
tion of the plaques (calculated as the number of cells: grade
1 = none, grade 2 = \50, grade 3 = at least 50), a linear
correlation in mRNA expression was observed in grade 1
mRNA expression in atherosclerotic plaques
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(R = 0.50, p = 0.04) and grade 3 (R = 0.99, P = 0.003)
(Table 4). No significant correlation was found for the
other histological features (p [ 0.05, data not shown).
COX-2 and TLR4
In the entire population, an increased linear correlation was
observed between COX-2 and TLR4 mRNA expression
moving from grade 2 (R = 0.43, p = 0.009) to grade 3
(R = 0.69, p = 0.03) considering the degree of the overall
plaque instability. Considering the degree of foam cells, we
observed a statistically significant linear correlation only in
grade 1 (R = 0.51, p = 0.01) (Table 4). No significant
correlation was found for the other histological features
(p [ 0.05, data not shown).
mRNA expression quantification
When stratifying by the degree of the plaque instability in
grade 3 plaque instability group, a significant overexpres-
sion of COX-2, TLR4 and IL1-b was observed in T2D
patients compared to non-T2D patients. When stratifying
by the degree of foam cells, we observed a higher COX-2
and IL1-b mRNA expression level (p \ 0.01 for both) in
T2D compared to non-T2D patients [Fig. 1]. No statisti-
cally different mRNA expression was observed for any of
the other histological features and risk factors analyzed
(data not shown).
Linear regression analysis
In the stepwise analysis, the presence of TLR4 and IL1-b
mRNA expression along with T2D status and smoking
habit showed that COX-2 expression is determined, in an
additive way, by T2D status and IL1-b expression (p-value
of the model \0.0001, adjusted R2 = 0.45), but not TLR4
expression. Indeed, in our multi-variable linear regression
model, the variable TLR4 was not statistically significant
even if it strongly correlated with COX-2 expression. To
further assess whether TLR4 could be an important vari-
able, a likelihood ratio test was used to compare the fit of
Table 2 Characteristics of the study patients
Grade
1 2 3 4
n T2D subjects/N subjects
Plaque instability 4/14 7/34 4/9 0
Foam cells 6/28 3/12 4/9 0
Lipid core 3/7 5/19 6/19 0
Hemorrhage 8/10 2/12 4/18 0
Surface thrombus 9/25 1/4 4/11 0
Fibrous tissue 1/8 10/25 3/7 0
Neovascularization 10/26 2/10 2/4 0
Calcification 0/2 3/11 11/27 0
Rupture fibrous cap 2/8 4/12 8/20 0
Inflammatory cells 1/4 4/17 7/17 1/4
Histological analysis. Number of patients with T2D divided into the
grades of histological features. Characteristics of the degree of plaque
instability were established on the basis of inflammatory infiltrate,
according to Lovett et al. [19]
n subjects = total number of subjects for each grade
Table 1 Characteristics of the study patients
T2Da (n = 16) non-T2D (n = 43)
Symptomatic Asymptomatic Symptomatic Asymptomatic
Female 2 4 1 10
Male 5 5 17 15
Age (mean ± SD) 70 ± 10 73 ± 7 70 ± 11 73 ± 7
72 ± 9 72 ± 9
Risk factors
Smoking habit (29 ± 19 cigarettes/day) 4/7 3/9 8/18 7/25
Hypertension 6/7 8/9 11/18 22/25
On ace inhibitor therapy 4/6 7/8 8/11 8/22
Dyslipidemia 5/7 6/9 9/18 19/25
On statin therapy 3/5 3/6 8/9 10/19
Clinical information, risk factors and current therapy divided in T2D and non-T2D patients. Symptomatic patients presented transient ischemia
attack (TIA) or ischemic stroke. Asymptomatic patients did not present TIA or ischemic stroke at the time they underwent carotid
endarterectomy
ACE angiotensin converting enzyme, n number of subjects, T2D type 2 diabetes, Yrs years
a Missing information for 1 patient
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two nested models, one with and one without TLR4. The
test showed that the presence of TLR4 in the multi-variable
model did not influence the level of COX-2 mRNA
expression. Thus, the most parsimonious model that
describes COX-2 mRNA expression is represented, in an
additive way, by T2D status and IL1-b mRNA expression
levels. To further investigate whether IL1-b might act as a
mediator variable between the risk factor T2D and COX-2
expression, the Baron and Kenny [31] analytic procedure
was used. The method showed that expression of COX-2 is
influenced by T2D status (57 %) and, to a lesser extent
(43 %), by the activation of IL1-b that would act as a
mediator variable.
Discussion
COX-2, TLR-4, IL1-b
Atherothrombotic cardiovascular disease is the leading
cause of death worldwide despite significant progress in the
management of critical risk factors [32]. A major reason
for this trend is the ongoing epidemic of obesity-induced
insulin resistance and T2D [33]. The mechanisms that
promote an inflammatory environment and accelerated
atherosclerosis in diabetes are poorly understood. A central
regulator of inflammation is NF-jB [34], a transcriptional
complex activated by various stimuli including cytokines,
oxidized LDL, lipopolysaccharide and oxidant stress [35],
all players in atherosclerosis development. In particular,
COX-2 is targeted by NF-jB, and its role in inflammation
has been demonstrated in several studies [12, 36], includ-
ing atherosclerosis [16]. Activation of NF-jB by TLR4
signaling and the role of TLR4 in inflammation through a
COX-2 dependent pathway have been well documented
[24, 37, 38]. Furthermore, recent studies have demonstrated
that COX-2 expression may be stimulated by IL1-b in
smooth muscle cells [39] and tendon cells [40]. Studies on
Table 4 Pearson correlation between COX-2 and IL1-b, and COX-2
and TLR4 gene expression considering the degree of two histological
features (degree of plaque instability and number of foam cells) in the
entire population analyzed
Correlation COX-2/IL1-b
Plaque instability Foam cells
Grade R p-value R p-value
3 0.75 0.030 0.99 0.003
2 0.61 0.001 NA NA
1 0.68 0.130 0.50 0.046
Correlation COX-2/TLR4
Plaque instability Foam cells
Grade R p-value R p-value
3 0.69 0.030 0.11 0.780
2 0.43 0.009 0.90 0.090
1 0.16 0.560 0.51 0.011
Plaque instability (grade 1 = stable, grade 2 = probably stable, grade
3 = probably unstable), Foam cells = Number of foam cells (grade
1 = none, grade 2 = \50, grade 3 = at least 50)
R Pearson coefficient, NA Data not available
Table 3 Mean and standard deviation of COX-2, IL1-b and TLR4 normalized gene expression in risk factor subgroups
COX-2 IL1-b TLR4
Mean ± SD Mean ± SD Mean ± SD
Type 2 diabetesa Yes (16) No (43) Yes (16) No (43) Yes (16) No (43)
1.67 ± 1.45 0.84 ± 0.72 p \ 0.01 3.25 ± 2.41 1.04 ± 0.77 p \ 0.01 1.09 ± 0.42 0.94 ± 0.38 ns
Smoking habita Yes (22) No (37) Yes (22) No (37) Yes (22) No (37)
1.57 ± 1.27 0.68 ± 0.53 p \ 0.01 1.93 ± 1.97 1.20 ± 1.12 ns 1.08 ± 0.41 0.90 ± 0.36 ns
Hypertensiona Yes (47) No (12) Yes (47) No (12) Yes (47) No (12)
1.1 ± 1.05 0.8 ± 0.73 ns 1.64 ± 1.73 1.28 ± 1.18 ns 0.98 ± 0.40 0.96 ± 0.38 ns
Dyslipidemiaa Yes (39) No (20) Yes (39) No (20) Yes (39) No (20)
1.21 ± 1.16 0.74 ± 0.50 ns 1.73 ± 1.84 1.31 ± 1.22 ns 1.20 ± 0.39 0.90 ± 0.39 ns
Sex M (45) F (15) M (45) F (15) M (45) F (15)
1.07 ± 1.05 0.96 ± 0.84 ns 1.65 ± 1.75 1.24 ± 1.12 ns 0.92 ± 0.37 0.11 ± 0.43 ns
Age Beta Beta Beta
-0.01 ns -0.007 ns -0.006 ns
COX-2, IL1-b and TLR4 mRNA values were measured by real-time RT-PCR and normalized to GAPDH (Glyceral dehyde-3-phosphate
dehydrogenase) and TBP (TATA box-binding protein). In brackets () the number of subjects for each group
p p-value, ns not statistically significant, sd standard deviation, Beta linear regression coefficient, ns not statistically significant (p-value [ 0.05)
a Missing information for 1 subject
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animal models reported that TLR4 activation and signaling
mediates the synthesis of COX-2 [41, 42] and that TLR4
activation can be induced by hyperglycemia in THP-1
human monocytic cell line [43].
mRNA expression in plaques
Although a strong correlation between COX-2 and TLR4
was observed in T2D patients, TLR4 expression failed to
account for COX-2 expression levels in our multi-variable
linear regression model and it had to be excluded. How-
ever, the Pearson correlation found between COX-2 and
TLR4 mRNA expression at foam cells grade 1 could
support the hypothesis that the TLR4 receptor is important
in the pathogenesis of atherosclerosis by promoting foam
cell formation [44]. Activation of TLR4 stimulates mono-
nuclear phagocytes to secrete chemokines which are
recognized for their involvement in the recruitment of
monocytes and T lymphocytes in the arterial wall [45].
The COX-2 mRNA expression is regulated by a broad
spectrum of mediators involved in inflammation, through
numerous intracellular pathways, varying between cell
types and cellular stimuli [46]. In this study, we observed a
significant coordinated overexpression of COX-2 and IL1-
b in atherosclerotic plaques of T2D patients and a com-
paratively weaker coordinated up-regulation in non-T2D
patients. Furthermore, the overexpression of COX-2 is
significantly increased in T2D patients with a grade 3
plaque instability (both foam cells and overall plaque
instability) while it is not statistically significant in grade 1
and 2. This supports the hypothesis that COX-2 may have a
different biological role and relevance according to the
phase of atherosclerosis progression. IL1-b is also over-
expressed in T2D patients with a grade 3 plaque instability
(both foam cells and overall plaque instability) enhancing
the role of T2D in inducing IL1-b expression as suggested
by a previous study [47]. The strong correlation between
COX-2 and IL1-b in grade 2 and 3 plaque instability could
indicate the progressive involvement of IL1-b in the
inflammation process and plaque destabilization. Expres-
sed by multiple cell types in the plaque, particularly foam
cells, IL1-b has a negative impact on the health of vascular
smooth muscle cells. It leads to the recruitment in the
vasculature of monocytes and activated platelets, which
secrete IL1-b to form an inflammatory feed-forward loop
(auto-stimulation) [48]. A part of histological features were
not completely available for all the patients at this time.
A model linking COX-2, IL1-b and T2D in pro-
inflammation
The model based on linear regression is consistent with
COX-2 overexpression being dependent on T2D status and,
to a lesser extent, the mRNA levels of IL1-b mRNA
expression. This model would comprise a three-variable
system in which two causal paths (the direct impact of the
independent variable (T2D) and the impact of IL1-b) feed
into the outcome variable, COX-2 mRNA expression. The
Baron and Kenny model analysis, which used linear
regression coefficients to measure the extent to which T2D
(independent variable) influenced COX-2 mRNA expres-
sion through IL1-b (mediator), suggests that activation of
COX-2 is mediated, at least in part, through an IL1-b
dependent pathway. Protein analysis is necessary to eval-
uate the level of protein expression and it is a potential
second step to this work as well as to augment the number
Fig. 1 Comparison of COX-2,
TLR4 and IL1-b gene
expression between T2D and
non-T2D subjects stratifying by
grade 3. Overall plaque
instability (grade 3 = probably
unstable) and grade 3 number of
foam cells (grade 3 = at least
50 cells). The other grades and
histological features were not
statistically significant. ns not
statistically significant (p-
value [ 0.05), * \0.05, **
\0.01, T2D: subjects with type
2 diabetes
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of subjects. Different studies demonstrate how glucose
promotes the expression of COX-2 through the activation
of IL1-b in mesangial cells [26], and islets of Langerhans
[27]. Animal studies suggest that exposure to IL1 promotes
atherogenesis; whereas, loss of IL1-b function associates
with reduced atherosclerotic lesions [49]. Our findings
estimate that the contribution of IL1-b to total COX-2
mRNA expression, would be about 43 % in the plaque of
T2D atherosclerotic patients (about 30 % in non-T2D
patients). Like T2D, type 1 diabetes (T1D) is a risk factor
linked to atherogenesis through the production of prosta-
glandins in a COX-mediated inflammation [50]. T1D leads
to an inflammatory process in which there is a significant
increase of cytokines (IL-1, IL-6, IL-18, and TNF-a) [51,
52]. Direct blockade of IL1-b has been studied extensively
as a therapeutic strategy for T1D at the preclinical level
[53]. Our results indicate that it is worth investigating
whether anti-inflammatory agents targeting IL-1b could
decrease significantly COX-2 mRNA expression levels;
and thus, diminish the augmented inflammatory response.
In turn, a diminished inflammatory response may reduce
the probability of plaque disruption and, consequently, the
risk of ischemic stroke.
Conclusions
Our results support the hypothesis that T2D pathology
contributes in vivo to increase the inflammatory process
associated with the atherosclerotic plaque formation, as
shown by an increment of COX-2 and IL1-b mRNA
expression.
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